Transplantation and Cellular Therapy Journal

The official journal of @ASTCT.

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This 15-year case series highlights diagnostic challenges of TB after #alloHCT. Only 3 of 7 screened patients tested positive, while 3 of 10 patients with confirmed TB died, underscoring limitations of current screening https://t.co/DR8LToyxiW: https://t.co/3eKG27NUyj

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

The November issue of 'Transplantation and Cellular Therapy,' is now available online: https://t.co/RhWwkIqKeR

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This Engraft Learning Network study found substantial variation in chronic #GVHD screening practices, with infrequent use of NIH scoring tools and patient-reported outcomes. Findings informed a practical screening bundle to support earlier recognition. https://t.co/SRtZY1d4Hn

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This nationwide registry analysis found that female-to-male allogeneic #HCT was associated with poorer survival outcomes only in recipients aged ≥40 years, highlighting the importance of recipient age when considering female donors for male patients. https://t.co/s1NMdqTFiG

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. https://t.co/sWshCKSBQw

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This propensity score-matched analysis found that single-dose high-dose melphalan reduced severe gastrointestinal, renal and hepatic toxicities compared with split-dose conditioning, with no differences in survival or Day +90 response rates. Read: https://t.co/lU7TruY4ip

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This critical review examines tools for predicting #CART toxicities, highlighting EASIX for severe CRS and ICANS and CAR-HEMATOTOX for prolonged cytopenia. Integrating clinical scores, CAR-T kinetics and imaging biomarkers may improve risk stratification. https://t.co/TCR3lOnXAu

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This study found that elevated plasma desmosine was associated with lung function decline and greater skin sclerosis severity in chronic #GVHD, highlighting its potential as a biomarker for pulmonary and cutaneous involvement. https://t.co/S2FMsnvpoW

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

The October issue of 'Transplantation and Cellular Therapy,' is now available online: https://t.co/RhWwkIqKeR

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This study found that ≥10% FEV1 decline affected ~48% of #alloHSCT recipients and was the strongest predictor of post-transplant mortality. Mortality risk remained elevated even after FEV1 recovery. Read: https://t.co/p94GVdiroc

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This CIBMTR analysis found no outcome differences among conditioning regimens in pediatric B cell acute lymphoblastic leukemia. MMUD HCT was associated with inferior DFS or OS vs MUD while UCB showed no relapse reduction advantage. Read: https://t.co/c6ZwhbDRHl

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This study confirms the prognostic value of MRD negativity in #pPCL for the first time. Findings also support that #ASCT can potentially provide response and survival benefits in the era of novel agents. Read: https://t.co/x3uYxyZDQj

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This real-world study found that patients with melanoma treated with commercial lifileucel had survival outcomes similar to the pivotal #TIL trial. However only half of patients referred ultimately received therapy. Read the full study: https://t.co/pszGPx5t8R

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This ASTCT expert panel commentary reviews third-party virus-specific T cells for refractory viral infections after #HCT and examines regulatory manufacturing and distribution barriers limiting broader and more equitable access. #VST Read more: https://t.co/qgscl3IXhO

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

Read on updates to the 2012 ASBMT acute #GVHD guidelines, including consensus recommendations on acute GVHD staging and grading, the clinical role of biomarkers and risk-stratification tools and acute GVHD treatment. https://t.co/mBcFZFXeBy

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

Study found that coronary artery calcification identified during pretransplant evaluation predicted non-relapse mortality in patients receiving PTCy. Among elderly patients without known coronary artery disease, it was associated with inferior survival. https://t.co/mrx8S8vbEM

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

Read on updates to the 2012 ASBMT acute #GVHD guidelines, including consensus recommendations on acute GVHD staging and grading, the clinical role of biomarkers and risk-stratification tools and acute GVHD treatment. https://t.co/mBcFZFXeBy

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This real-world analysis found that prophylactic anakinra did not reduce grade ≥3 #CART associated neurotoxicity syndrome. No survival or response rate differences observed with anakinra prophylaxis. Read: https://t.co/viwgrX9UVL

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This study provides first evidence linking Lnc-BRMS1L-4 and ZEB1-AS1 to acute lymphoblastic leukemia and clinical features. Read the full study: https://t.co/XN6aq6CZaQ

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

The September issue of 'Transplantation and Cellular Therapy,' is now available online: https://t.co/RhWwkIqKeR
@ELShematology